Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 171.97% | 185.24% | -39.87% | -4.90% | 20.53% |
| Total Depreciation and Amortization | 21.85% | 14.81% | -13.87% | -6.42% | -18.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -618.55% | -218.68% | 2.45% | -67.78% | 96.65% |
| Change in Net Operating Assets | -31.45% | -195.99% | -80.30% | 259.51% | 3.83% |
| Cash from Operations | 173.91% | -100.55% | -227.46% | 612.51% | 233.58% |
| Capital Expenditure | 2.28% | 81.56% | -- | -226.68% | -2,818.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.83% | 81.56% | -- | -226.68% | -2,544.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.27% | -5.45% | -7.41% | -7.62% | -6.80% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -3.42% | -22.92% | 44.87% | 49.67% | 51.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4.27% | -9.52% | 36.69% | 9.60% | 31.13% |
| Foreign Exchange rate Adjustments | 164.00% | -248.28% | -30.00% | 521.59% | -176.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.39% | 32.53% | -572.85% | 227.59% | -175.39% |